Is $935 million enough to send a message? We may soon find out.

Elevance’s most recent quarterly report estimated it will cost $935 million (plus $565 million or minus $585 million) to avoid sanctions from the Centers for Medicare and Medicaid Services (CMS).

CMS threatened the payer with sanctions in a Feb. 27 letter, including an enrollment freeze, unless Elevance corrects years of what it says are improperly submitted Medicare Advantage (MA) risk adjustment data and makes sure this doesn’t happen again. The original submitted data resulted in CMS sometimes paying Elevance more than it was owed for care—overpayments that weren’t paid back, the letter says.

The deadline for corrections was originally March 30, per the letter, but was extended first until May 30 and then through July 31, Elevance CEO and President Gail Boudreaux said during an April 22 earnings call.

But will it really make a difference?—CC

It’s important to stay up to date on who leads healthcare companies, whether you work in the industry or are just concerned about downstream effects on access and costs.

Each month, we make a list of some of the leaders who were hired, fired, or retired from businesses ranging from major companies to startups in order to keep our readers informed.

Welcome to April 2026’s On Rotation!

Have a job announcement to share? Drop Caroline an email at [email protected].

Andrew Baum. Pfizer’s chief strategy and innovation officer is exiting his role, as reported by Reuters on April 20. He will serve as a senior strategic advisor to company CEO Albert Bourla, then leave altogether by the end of the year, per an analyst note from BMO Capital Markets.

Alexander Billioux. Cityblock Health, a healthcare provider focused on Medicaid and dually eligible patients, announced Billioux as its new chief health officer on April 23. He comes to the role after five years at UnitedHealthcare, where he most recently served as government programs chief medical officer.

See the full list here.—CC

At Target, the baby aisle is quickly becoming a one-stop shop for parents.

As part of its latest turnaround effort appealing to “busy families,” the retailer is courting more premium brands in a bid to expand its baby aisle, and now pediatric medicine brand Genexa is joining the lineup after making the leap from the medicine aisle.

The move places Genexa’s pain, fever, cold and flu, and allergy medicines alongside diapers, wipes, and popular registry items, in what co-founder David Johnson called a “very novel” arrangement, given that most of its OTC products are sold in pharmacy sections.

Ever since the closure of category killer Buy Buy Baby, Johnson said, there has been a lack of retailers offering a “whole experience,” where diapers, strollers, formula, and medicine are all available in the same department.

Genexa is projecting that its products will make up 15% of Target’s infant OTC drug category, as it expands the number of SKUs available and whips up special offerings such as “registry-ready bundles” aimed at supplying parents with everything they need for “Baby’s First Sick Day.”

Keep reading on Retail Brew.—AV

AI has begun to influence doctor’s offices worldwide as its market
prediction is set to reach over $3 billion by 2030. Here’s what you need to know about virtual agents and how the AI voice agent is tackling healthcare issues.

Real jobs, shared through real communities. CollabWORK brings opportunities directly to Healthcare Brew readers—no mass postings, no clutter, just roles worth seeing. Click here to view the full job board.